Dr Alita Miller

Alita Miller is the Head of Bioscience at EntasisTherapeutics, a small biotech focused on the discovery and and development of novel antibiotics to treat serious Gram-negative infections. Alita holds a BA in Chemistry from Kalamazoo College and a PhD in Biochemistry & Molecular Biology from the University of Chicago. Her postdoctoral work was on bacterial pathogenesis at the University of Michigan with Vic DiRita.  Alita spent over a decade in the Pfizer Antibacterials Unit where she worked on both large and small molecule anti-infective projects.  Alita joined AstraZeneca in 2013 as an Associate Director of Infection and was a founding member of Entasis when it was spun out of AstraZeneca Infection in May of 2015. Alita serves on several advisory boards and is a permanent member of the NIH grant review panel for Drug Discovery and Resistance. Her current research interests include understanding the molecular drivers of bacterial antibiotic uptake.

Session 7: New drug targets
Wednesday 5 April 
Chair: Professor Vicky Avery

Supported By